JP2007504259A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504259A5
JP2007504259A5 JP2006525704A JP2006525704A JP2007504259A5 JP 2007504259 A5 JP2007504259 A5 JP 2007504259A5 JP 2006525704 A JP2006525704 A JP 2006525704A JP 2006525704 A JP2006525704 A JP 2006525704A JP 2007504259 A5 JP2007504259 A5 JP 2007504259A5
Authority
JP
Japan
Prior art keywords
tumor
agent according
made agent
pharmaceuticals
pharmaceuticals made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/009737 external-priority patent/WO2005020989A1/en
Publication of JP2007504259A publication Critical patent/JP2007504259A/ja
Publication of JP2007504259A5 publication Critical patent/JP2007504259A5/ja
Pending legal-status Critical Current

Links

JP2006525704A 2003-09-02 2004-09-01 エポチロンでの癌処置 Pending JP2007504259A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
PCT/EP2004/009737 WO2005020989A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Publications (2)

Publication Number Publication Date
JP2007504259A JP2007504259A (ja) 2007-03-01
JP2007504259A5 true JP2007504259A5 (cg-RX-API-DMAC7.html) 2007-10-25

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525704A Pending JP2007504259A (ja) 2003-09-02 2004-09-01 エポチロンでの癌処置

Country Status (9)

Country Link
US (2) US20060235059A1 (cg-RX-API-DMAC7.html)
EP (1) EP1663214A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007504259A (cg-RX-API-DMAC7.html)
CN (1) CN1870995A (cg-RX-API-DMAC7.html)
AU (1) AU2004268377B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414043A (cg-RX-API-DMAC7.html)
CA (1) CA2537057A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002393A (cg-RX-API-DMAC7.html)
WO (1) WO2005020989A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512459A4 (en) * 2009-12-15 2013-08-07 THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE60225666T2 (de) * 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
ES2297189T3 (es) * 2002-08-02 2008-05-01 Novartis Ag Derivados de epotilona.
CA2510610A1 (en) * 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
EP1641449A1 (en) * 2003-06-27 2006-04-05 Novartis AG Cancer treatment with epothilones

Similar Documents

Publication Publication Date Title
Wu et al. Nanomedicine applications in the treatment of breast cancer: current state of the art
Ko et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
Patel et al. Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: a comprehensive review
Lu et al. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy
Rivera et al. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors
JP2008530248A5 (cg-RX-API-DMAC7.html)
JP2006503919A5 (cg-RX-API-DMAC7.html)
Lee et al. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
Yogesh et al. Biosynthesized platinum nanoparticles inhibit the proliferation of human lung-cancer cells in vitro and delay the growth of a human lung-tumor xenograft in vivo:-In vitro and in vivo anticancer activity of bio-Pt NPs
JP2021500349A5 (cg-RX-API-DMAC7.html)
JP2003533485A5 (cg-RX-API-DMAC7.html)
CN110478487B (zh) 一种大环内酯化合物在逆转肿瘤多药耐药增强抗肿瘤疗效方面的应用
Muggia et al. Novel taxanes
US20090069394A1 (en) Cancer treatment with epothilones
JP2022527334A5 (cg-RX-API-DMAC7.html)
Denduluri et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
JP2024511354A5 (cg-RX-API-DMAC7.html)
Cortés-Funes New treatment approaches for lung cancer and impact on survival
Bystricky et al. Patupilone in cancer treatment
JP2026071339A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
CN107041886A (zh) 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
Casaluce et al. Emerging mitotic inhibitors for non-small cell carcinoma
Zhang et al. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors
Kim et al. Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
JP2005511663A5 (cg-RX-API-DMAC7.html)